AGTC Genomics

💧 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱 𝐜𝐭𝐃𝐍𝐀 𝐋𝐢𝐪𝐮𝐢𝐝 𝐁𝐢𝐨𝐩𝐬𝐲 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 Say goodbye to invasive procedures! With LiquidDx, you can now monitor and detect cancer through a simple blood draw using circulating tumor DNA (ctDNA). 🌟 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱? ✔Non-Invasive: Just a blood draw—no surgery, no hospital admission. ✔Comprehensive: Profiles 523 genes and key genomic markers like TMB, MSI, and HRR. ✔Actionable Insights: Offers guidance on FDA-approved therapies and immunotherapies. ✔Fast Results: Delivered within 7–14 working days from our ISO 15189-certified lab. 🚀 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐋𝐢𝐪𝐮𝐢𝐝𝐃𝐱 ● Alternative to Tissue Biopsy: Ideal when a tissue sample is inaccessible or unavailable. ● Monitor Therapeutic Response: Track treatment effectiveness and detect residual disease early. ● Identify New Mutations: Stay ahead by detecting tumor heterogeneity and acquired resistance. ● Convenient & Reliable: Suitable for routine monitoring and optimizing personalized treatments. 🧬 𝐇𝐨𝐰 𝐭𝐨 𝐆𝐞𝐭 𝐒𝐭𝐚𝐫𝐭𝐞𝐝 1️⃣ Order the test with your healthcare provider. 2️⃣ Provide a blood sample—no complicated preparation needed. 3️⃣ Receive detailed genomic insights for targeted therapy or clinical trial options. 💡 LiquidDx gives patients and providers a non-invasive, fast, and precise alternative to traditional tissue biopsies, transforming cancer care and enabling precision medicine. 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com #LiquidBiopsy #PrecisionMedicine #ctDNA #AGTCGenomics #CancerCare #PersonalizedMedicine #HealthcareInnovation

𝐖𝐚𝐫𝐦 𝐃𝐞𝐞𝐩𝐚𝐯𝐚𝐥𝐢 𝐆𝐫𝐞𝐞𝐭𝐢𝐧𝐠𝐬 𝐟𝐫𝐨𝐦 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬! Wishing you and your loved ones a joyous and bright Deepavali filled with happiness, prosperity, and new beginnings. May this festival of lights illuminate your life with hope and positivity. Happy Deepavali! Best wishes, The AGTC Genomics Team

🔬 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐰𝐢𝐭𝐡 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 At AGTC Genomics, we offer a wide range of genomics services designed to meet the most demanding research needs. Whether you're working on population genomics, oncology, agriculture, or personalized medicine, our cutting-edge technology and expertise ensure you get the insights you need—quickly and accurately. 🌟 𝐎𝐮𝐫 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 ✔Whole Genome Sequencing (WGS): Explore the full genetic composition of an organism. ✔Whole Exome Sequencing (WES): Focus on coding regions to identify disease-causing mutations. ✔Single Cell Sequencing: Uncover cellular heterogeneity for immune and cancer research. ✔Metagenomic Sequencing: Understand complex microbial communities through 16S/18S or shotgun metagenomics. ✔Transcriptome Sequencing: Study gene expression and regulatory networks with RNA-Seq and mRNA analysis. ✔Epigenome Sequencing: Profile methylation patterns with WGBS and DNA methylation microarrays. 🚀 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬? ● Competitive Pricing: Transparent, all-inclusive pricing models. ● Exceptional Data Quality: Over 90% of bases scoring Q30 or higher. ● Optimized Workflows: Efficient processes to ensure reliable results. ● Dedicated PhD Experts: Personalized support throughout the project. ● End-to-End Data Security: All services conducted in Malaysia, ensuring full data sovereignty. 🔧 𝐇𝐨𝐰 𝐈𝐭 𝐖𝐨𝐫𝐤𝐬 1️⃣ Send us your samples and project information. 2️⃣ Monitor progress with your dedicated project manager. 3️⃣ Receive ready-to-use results—aligned, analyzed, and secure BAM/VCF files. 💡 With AGTC Genomics, your data transforms into discovery. Our expert teams are ready to support you with state-of-the-art technology for any research project. 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com #Genomics #PrecisionMedicine #AGTCGenomics #NGS #GenomeSequencing #Transcriptomics #Epigenetics #ScientificResearch

🔬 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐏𝐫𝐞𝐜𝐢𝐬𝐞𝐃𝐱 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐆𝐞𝐧𝐞 𝐏𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 At AGTC Genomics, we empower precision medicine with PreciseDx, a comprehensive genomic profiling solution designed to maximize the identification of actionable biomarkers and optimize patient outcomes. 🧬 𝐖𝐡𝐲 𝐏𝐫𝐞𝐜𝐢𝐬𝐞𝐃𝐱? ✔Broad Biomarker Analysis: Profile 523 genes including tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination repair (HRR) markers. ✔Actionable Insights: Aligns with FDA-approved therapies, clinical trial options, and international guidelines. ✔Applicable for Solid & Blood Cancers: Offers pan-cancer and cancer-specific panels. ✔Fast & Reliable: Results delivered within 7–14 working days from our ISO 15189-certified lab. 🚀 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 ● Single Test, Multiple Biomarkers: Detects various mutations (SNVs, indels, CNVs, gene fusions) in one test, minimizing the need for rebiopsy. ● Maximizes Sample Efficiency: Avoids sequential testing by consolidating results into a multiplex assay. ● Therapy Matching: Identifies targeted therapies, immunotherapies, and emerging clinical trials based on individual tumor profiles. ● Continuous Reanalysis: Leverage the latest discoveries without retesting or rebiopsy. 🌟 𝐇𝐨𝐰 𝐭𝐨 𝐆𝐞𝐭 𝐒𝐭𝐚𝐫𝐭𝐞𝐝 1️⃣ Order the test via your healthcare provider. 2️⃣ Submit biopsy or blood samples to our lab. 3️⃣ Receive comprehensive insights for personalized treatment planning. 💡 PreciseDx gives you more than just answers—it offers opportunities for better treatment outcomes through precision therapy and cutting-edge clinical trials. For more information: 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com #GenomicProfiling #PrecisionMedicine #CancerCare #AGTCGenomics #PersonalizedTreatment

🔍 𝐃𝐞𝐭𝐞𝐜𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐄𝐚𝐫𝐥𝐲 𝐰𝐢𝐭𝐡 𝐂𝐚𝐧𝐜𝐞𝐫𝐒𝐜𝐫𝐞𝐞𝐧𝐃𝐱 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 CancerScreenDx is revolutionizing early cancer detection! A single blood test can now identify over 110 types of cancer, giving you a proactive edge to fight cancer when it's most treatable. 🌟 𝐖𝐡𝐲 𝐂𝐚𝐧𝐜𝐞𝐫𝐒𝐜𝐫𝐞𝐞𝐧𝐃𝐱? ✔Comprehensive Detection: Screen for 110+ types of cancer, surpassing traditional methods. ✔Accurate & Predictive: Pinpoints cancer origin with precision for early intervention. ✔Non-Invasive: One simple blood draw for easy and accessible screening. Fast Turnaround: Results within 7–14 days from our ISO 15189-certified lab. 🧬 𝐇𝐨𝐰 𝐈𝐭 𝐖𝐨𝐫𝐤𝐬 CancerScreenDx detects circulating tumor DNA (ctDNA) in the blood, identifying cancer signals early and accurately predicting their source. This empowers patients and healthcare providers to take timely action with confidence. 🎯 𝐖𝐡𝐨 𝐒𝐡𝐨𝐮𝐥𝐝 𝐆𝐞𝐭 𝐓𝐞𝐬𝐭𝐞𝐝? ● Individuals aged 40+ for routine screening. ● Those with family history of cancer. ● People with previous cancer diagnoses seeking proactive monitoring. ● Anyone with symptoms such as unexplained weight loss, fatigue, or persistent pain. 🚀 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐄𝐚𝐫𝐥𝐲 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 ● Higher survival rates with timely treatment. ● Improved quality of life through reduced treatment burdens. ● Cost savings by avoiding advanced-stage treatments. 𝐎𝐫𝐝𝐞𝐫 𝐓𝐨𝐝𝐚𝐲 𝐚𝐧𝐝 𝐓𝐚𝐤𝐞 𝐂𝐨𝐧𝐭𝐫𝐨𝐥 𝐨𝐟 𝐘𝐨𝐮𝐫 𝐇𝐞𝐚𝐥𝐭𝐡! 1️⃣ Order the test through your healthcare provider. 2️⃣ Blood draw at your lab or clinic. 3️⃣ Receive your results in just 7-14 working days. For more information: 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com #CancerDetection #AGTCGenomics #EarlyDetection #CancerScreenDx #PrecisionMedicine #HealthcareInnovation

🚀 𝐄𝐦𝐩𝐨𝐰𝐞𝐫 𝐘𝐨𝐮𝐫 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐰𝐢𝐭𝐡 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 Transform your raw genomic data into actionable insights with AGTC Genomics' Bioinformatics Services—tailored to meet your unique research needs. Whether you are exploring oncology, microbiomes, or drug discovery, our expertise ensures seamless integration from experiment planning to data interpretation. 🌟 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐀𝐆𝐓𝐂 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬? ✔Customized Solutions: Tailored bioinformatics support for diverse scientific projects. ✔Cutting-Edge Technologies: Utilize advanced sequencing, data analysis tools, and proprietary pipelines. ✔Wide-Ranging Expertise: Comprehensive services spanning genomics, transcriptomics, epigenomics, and more. ✔Dedicated Project Management: PhD-level experts guiding your project from start to publication. 🔬 𝐎𝐮𝐫 𝐁𝐢𝐨𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐜𝐬 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐚𝐭 𝐚 𝐆𝐥𝐚𝐧𝐜𝐞 ● Genomic Data Analysis: GWAS, de novo sequencing, and structural variant calling. ● Metagenomics & Microbiome Analysis: Pathogen surveillance, AMR monitoring, and environmental studies. ● Epigenomics & Methylation Analysis: DNA methylation profiling, ATAC-seq, and bisulfite sequencing. ● Transcriptomic Analysis: Whole transcriptome sequencing, mRNA-Seq, and small RNA analysis. 🧬 𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 ● Fast Turnaround: Timely data analysis with publication-ready results. ● Scalable Solutions: Ideal for academic, biotech, and pharmaceutical projects. ● Post-Project Support: Assistance with publications and further research. ● Seamless Communication: Direct access to our bioinformatics team for smooth project execution. 💡 From data to discovery, AGTC Genomics empowers your research with precision and reliability. Collaborate with us and experience bioinformatics as a service—designed to unlock new scientific breakthroughs. 📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com #Bioinformatics #GenomicData #MicrobiomeResearch #PrecisionMedicine #DataDrivenResearch #AGTCGenomics #BigDataInScience #ScientificBreakthroughs

🚀 𝐓𝐚𝐤𝐞 𝐂𝐨𝐧𝐭𝐫𝐨𝐥 𝐨𝐟 𝐘𝐨𝐮𝐫 𝐇𝐞𝐚𝐥𝐭𝐡 𝐰𝐢𝐭𝐡 𝐂𝐚𝐧𝐜𝐞𝐫𝐑𝐢𝐬𝐤𝐃𝐱 𝐇𝐞𝐫𝐞𝐝𝐢𝐭𝐚𝐫𝐲 𝐂𝐚𝐧𝐜𝐞𝐫 𝐒𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐛𝐲 𝐀𝐆𝐓𝐂 𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 🌏 Cancer remains one of the leading global health challenges, with family history often playing a significant role. Gain clarity, take preventive action, and empower your future with CancerRiskDx—a cutting-edge genetic test designed to identify inherited cancer risks.  🔬 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐀𝐜𝐫𝐨𝐬𝐬 50+ 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐲𝐩𝐞𝐬 ✔Evaluate 316 genes linked to hereditary cancers including breast, ovarian, prostate, and colorectal cancers, and many more.  ✔Identify mutations associated with cancers affecting major organ systems—from skin to brain, gastrointestinal to hematological malignancies.  ✨ 𝐖𝐡𝐲 𝐂𝐡𝐨𝐨𝐬𝐞 𝐂𝐚𝐧𝐜𝐞𝐫𝐑𝐢𝐬𝐤𝐃𝐱? ✔Accurate Results: Utilizing Next Generation Sequencing (NGS) technology with 99.9% accuracy.  ✔Speedy Turnaround: Results within 7–14 working days through our ISO 15189-certified lab locally.  ✔Cost-Effective: One test reveals multiple answers, saving both time and money.  📈 𝐖𝐡𝐞𝐧 𝐭𝐨 𝐂𝐨𝐧𝐬𝐢𝐝𝐞𝐫 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 - Family history of cancer diagnosed at age 50 or younger.   - Multiple cases of cancer or tumors within the same side of the family.   - Individuals seeking to understand the prevalence of cancer in their family.  💡 𝐇𝐨𝐰 𝐈𝐭 𝐖𝐨𝐫𝐤𝐬 1️⃣ Order the test.   2️⃣ Provide blood, saliva, or buccal swab samples.   3️⃣ Receive insights that empower you and your loved ones to take preventive steps.  🧬 𝐈𝐧𝐟𝐨𝐫𝐦𝐞𝐝 𝐂𝐡𝐨𝐢𝐜𝐞𝐬 𝐟𝐨𝐫 𝐚 𝐁𝐫𝐢𝐠𝐡𝐭𝐞𝐫 𝐅𝐮𝐭𝐮𝐫𝐞 - Understand your cancer risk to pursue enhanced surveillance or preventive strategies.   - Make informed treatment decisions in partnership with your doctor.   - Provide family members with genetic insights to safeguard their future health.  📤 𝐄𝐚𝐬𝐲 𝐒𝐚𝐦𝐩𝐥𝐞 𝐓𝐫𝐚𝐧𝐬𝐩𝐨𝐫𝐭   Samples can be shipped via **regular mail at room temperature**, with liquid blood stable for 4 days.  Take charge of your health. **CancerRiskDx** gives you the knowledge to make informed decisions and live confidently.  For more information or to place your order:   📧 info@agtcgenomics.com 🌐 www.agtcgenomics.com 📍 AGTC Genomics Sdn Bhd, Bukit Jalil, Kuala Lumpur **#CancerScreening #HereditaryCancer #Genetics #AGTCGenomics #PrecisionMedicine #CancerRiskManagement**  

Recent advancements in molecular profiling have enabled the identification of potential therapeutic targets for biliary tract cancer (BTC). However, obtaining adequate tissue samples for genomic analysis remains a significant challenge in many cases. This study, conducted at CHA Bundang Medical Center, explores the use of circulating tumor DNA (ctDNA) as an alternative to tissue-based analysis and assesses its feasibility in guiding treatment for BTC. The study involved 102 patients with advanced BTC, using both tissue-based next-generation sequencing (NGS) and ctDNA analysis. The results showed an 84.8% concordance between ctDNA and tumor tissue mutations, with ctDNA identifying actionable alterations in 34.3% of patients. These included FGFR2 fusion, IDH1 mutations, microsatellite instability-high (MSI-high), ERBB2 amplification, and BRCA1/2 mutations. Notably, a novel FGFR2-TNS1 fusion was discovered through ctDNA, which was not captured by the tissue-based NGS panel. Additionally, the study found that higher somatic variant allele frequencies in ctDNA were associated with poorer survival outcomes following gemcitabine/cisplatin-based chemotherapy. This large-scale study is the first of its kind in Asia, demonstrating that ctDNA-based liquid biopsy offers acceptable concordance with tissue profiling for identifying therapeutic targets. It highlights the potential of ctDNA as a valuable complement to tissue-based genomic analysis, particularly when tissue samples are difficult to obtain. These findings underscore the promise of liquid biopsy in advancing personalized medicine for BTC, bringing new hope for precision oncology in challenging clinical scenarios. #Genomics #LiquidBiopsy #PrecisionMedicine #CancerResearch #BiliaryTractCancer

What an insightful and dynamic session we had today! Thank you, UKM Medical Molecular Biology Institute (UMBI), for hosting this landmark stakeholders' round table discussion on Public-Private Partnership in Precision Health Research for Malaysia. It was inspiring to see so many esteemed organizations come together, including: Universiti Putra Malaysia (UPM) Universiti Sains Malaysia (USM) Universiti Teknologi MARA (UiTM) IMU University (IMU) Monash University Malaysia Ministry Of Health, Malaysia (KKM) - Pharmacy Services Division AGTC Genomics Illumina PacBio Next Gene Scientific (distributor for Oxford Nanopore Technologies) Thermo Fisher Scientific Codon Genomics Sdn Bhd Oncode Scientific Sdn Bhd Genetics Biomed Global Amazon Web Services (AWS) Premier Integrated Labs Bioeconomy Corporation Academy of Sciences Malaysia Special thanks to the director and research fellows from UKM Medical Molecular Biology Institute (UMBI), whose participation was invaluable.

🎗️ 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 – 𝐓𝐡𝐢𝐬 𝐏𝐢𝐧𝐤 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 Traditional breast cancer treatments don’t always fit every patient’s needs. Genomic testing is changing that by identifying the most effective therapies, reducing side effects, and improving survival rates. 🧬 From personalized therapies to real-time monitoring with liquid biopsy, learn how genomic testing ensures the right treatment from the start and empowers patients to take control of their journey. Read the full article to explore how precision medicine is reshaping breast cancer care. #PinkOctober #BreastCancerAwareness #GenomicTesting #PrecisionMedicine #CancerCare #AGTCGenomics